Reassessment of the Correlation between the von Willebrand Factor Activity, the PFA-100®, and the Bleeding Time in Patients with von Willebrand Disease

Thromb Haemost 2001; 86(02): 715-716
DOI: 10.1055/s-0037-1616120

Letters to the Editor

Schattauer GmbH

Reassessment of the Correlation between the von Willebrand Factor Activity, the PFA-100^®, and the Bleeding Time in Patients with von Willebrand Disease

Ioana C. Nitu-Whalley

¹Centre and Haemostasis Unit, Royal Free and University College Medical School, London, UK

,

Christine A. Lee

¹Centre and Haemostasis Unit, Royal Free and University College Medical School, London, UK

,

Cedric Hermans

¹Centre and Haemostasis Unit, Royal Free and University College Medical School, London, UK

References
1 Veyradier A, Fressinaud E, Boyer-Neumann C, Trossaert M, Meyer D. von Willebrand factor ristocetin cofactor activity correlates with platelet function in a high shear stress system. Thromb Haemost 2000; 84: 727-8.
2 Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1: 307-10.
3 Murdock PJ, Woodhams BJ, Matthews KB, Pasi KJ, Goodall AH. von Willebrand factor activity detected in a monoclonal antibody-based ELISA: an alternative to the ristocetin cofactor platelet agglutination assay for diagnostic use. Thromb Haemost 1997; 78: 1272-7.
4 Fressinaud E, Veyradier A, Truchard F, Martin I, Boyer-Neumann C, Trossaert M, Meyer D. Screening for von Willebrand disease with a new analyser using high shear stress: a study of 60 cases. Blood 1998; 91: 1325-31.
5 Cattaneo M, Federici AB, Lecchi A, Agati B, Lombardi R, Stabile F, Bucciarelli P. Evaluation of the PFA-100 system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease. Thromb Haemost 1999; 82: 35-9.
6 Nitu-Whalley IC, Riddell A, Lee CA, Pasi KJ, Owens D, Enayat MS, Perkins SJ, Jenkins PV. Identification of type 2 von Willebrand disease in previously diagnosed type 1 patients: a reappraisal using phenotypes, genotypes and molecular modeling. Thromb Haemost 2000; 84: 998-1004.